Novo Nordisk - US emails worth copying

To inform the public and stakeholders that Novo Nordisk is taking legal action against Hims & Hers for marketing unsafe, unapproved versions of Wegovy® and Ozempic®, emphasizing patient safety and the company’s commitment to protecting FDA-approved treatments.

Novo Nordisk strategically frames its legal action not as a corporate dispute but as a moral defense of patient safety, directly linking Hims & Hers’ practices to life-threatening risks like immune responses and overdoses to evoke urgency and public sympathy.

By citing authoritative voices like the FDA, AMA, and Endocrine Society, the email leverages third-party credibility to reinforce its claims, transforming a legal notice into a public health warning that resonates with both consumers and medical professionals.

Add a visual element such as a warning icon or red banner near the headline to immediately signal urgency and danger, helping readers grasp the critical nature of the message before diving into text-heavy paragraphs. • Include a short, bolded summary box at the top that distills the legal action, key risks, and patient safety message into 3 bullet points, improving scannability for time-constrained readers and reinforcing the core message.

To announce a significant reduction in the US list price for Wegovy®, Ozempic®, and Rybelsus® to improve patient access, particularly for those whose out-of-pocket costs are tied to list price, while reinforcing Novo Nordisk’s commitment to affordability and equitable healthcare access.

Novo Nordisk strategically frames its price reduction not as a discount but as a systemic correction to address affordability barriers, directly tying the action to patient outcomes and healthcare equity, a narrative that builds trust while subtly positioning competitors as less socially responsible.

The email leverages clinical authority by embedding detailed safety and usage information within the announcement, transforming a pricing update into an educational moment that reinforces brand credibility and reduces patient hesitation through transparency and medical context.

Add a visual comparison chart or side-by-side pricing table showing old vs. new list prices for Wegovy®, Ozempic®, and Rybelsus® to make the 50–35% reduction immediately tangible and emotionally resonant for readers scanning the announcement. • Include a short patient testimonial or quote from a healthcare provider in the Hero Section to humanize the price reduction, reinforcing the message that this change directly improves real lives, not just balance sheets or policy metrics.

To introduce the newly launched Wegovy® pill to American consumers through a high-visibility Super Bowl ad campaign, positioning it as an accessible, science-backed weight management solution that shifts the conversation from shame to empowerment.

By featuring relatable celebrity athletes who openly share personal weight loss struggles, the campaign humanizes the medication and reframes weight management as a shared, achievable goal rather than a moral failing, making the product feel accessible and emotionally resonant.

The email strategically positions Wegovy® pill as the first and only oral GLP-1 medicine in the U.S., leveraging its FDA approval and clinical backing to build trust while differentiating it from injectables, thereby reducing perceived barriers to adoption among hesitant consumers.

The primary CTA 'View the full ad here' is passive and buried under dense text; it should be visually elevated with a button-style design and placed immediately after the hero message to capture attention before readers scroll past. • While the email includes detailed safety and usage information, it lacks a clear visual hierarchy or collapsible sections, which risks overwhelming readers, consider using accordions or progressive disclosure to make complex medical content digestible without sacrificing compliance.

To publicly denounce Hims & Hers for illegally compounding and misleadingly marketing unapproved semaglutide products, while reinforcing Novo Nordisk’s commitment to patient safety and FDA-approved standards.

Novo Nordisk strategically frames its response as a patient safety imperative, not just a corporate dispute, which builds public trust by positioning the brand as a guardian of regulatory integrity and medical ethics.

By explicitly contrasting its FDA-approved Wegovy® with untested compounded alternatives, the email leverages regulatory authority as a persuasive differentiator, subtly guiding consumers toward the legitimate, vetted product.

Add a visual comparison table or side-by-side graphic showing FDA-approved vs. compounded semaglutide to make the safety and regulatory differences instantly digestible for non-medical readers. • Include a short patient testimonial or quote from a healthcare provider affirming the importance of FDA-approved GLP-1 medications to humanize the message and strengthen emotional resonance.

To announce and educate healthcare professionals and stakeholders about the FDA’s approval of Sogroya® for three new pediatric indications, emphasizing its innovation as the first once-weekly growth hormone therapy and reinforcing Novo Nordisk’s leadership in rare disease treatment.

The email strategically positions Sogroya® not just as a new approval, but as a paradigm-shifting solution that reduces the treatment burden from 365 daily injections to just 52 weekly ones, directly addressing caregiver fatigue and improving adherence.

By embedding clinical trial data (REAL8) with specific patient subgroups and non-inferiority metrics, the email builds scientific credibility while making complex outcomes accessible to busy clinicians through concise, bullet-pointed summaries.

Add a visual comparison graphic (e.g., calendar icons) contrasting 365 daily injections vs. 52 weekly injections to reinforce the burden-reduction message more intuitively than text alone. • Include a brief patient or caregiver testimonial snippet, even anonymized, to emotionally anchor the clinical data and demonstrate real-world impact beyond trial metrics.